Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24918911 | 0.89 | USP2 (0.31) | GAAUSP2TSHRMEN1KMT2A | |
| SCHEMBL22965794 | 0.89 | CYP1A2 (0.35) | CYP1A2MEN1KMT2A | |
| SCHEMBL24287398 | 0.80 | CYP1A2 (0.36) | GAACYP1A2 | |
| SCHEMBL24433308 | 0.80 | KMT2A (0.31) | MEN1KMT2A | |
| SCHEMBL22803191 | 0.77 | KMT2A (0.33) | MEN1KMT2A | |
| SCHEMBL25641230 | 0.76 | CYP1A2 (0.34) | CYP1A2 | |
| SCHEMBL22965558 | 0.76 | CYP1A2 (0.40) | CYP1A2 | |
| SCHEMBL24433208 | 0.76 | CYP1A2 (0.33) | CYP1A2MEN1KMT2A | |
| SCHEMBL18484956 | 0.75 | KMT2A (0.36) | CYP1A2MEN1KMT2A | |
| SCHEMBL25003849 | 0.74 | MEN1 (0.33) | GAAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200390895-A1 | UNIVERSAL ABT COMPOUNDS AND USES THEREOF | KLEO PHARMACEUTICALS, INC. | 2020-12-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200390895-A1 | UNIVERSAL ABT COMPOUNDS AND USES THEREOF | CD47, MCL1, BCL9 | GAA 2911/4885CYP1A2 4647/4885USP2 1016/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.